🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs
5,568

Quick answer

Oncology: NovaPharmaNews indexes 5,568 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Page 68 of 116

  1. Raltitrexed

    The First People's Hospital of Lianyungang

    Inoperable Esophageal Cancer Stage I-III

    phase 2 small molecule active

    1 trial

  2. Raludotatug Deruxtecan

    Daiichi Sankyo

    Advanced/metastatic solid tumors including gynecological cancers (endometrial cancer, cervical cancer, and nonhigh- grade serous ovarian cancer) and genitourinary cancers (urothelial cancer and ccRCC)

    phase 2 small molecule active

    1 trial

  3. Raludotatug Deruxtecan (R-DXd)

    Merck KGaA, Darmstadt, Germany

    Gastrointestinal Cancer

    phase 2 mab active

    1 trial

  4. Ramucirumab

    Eli Lilly and Company

    Gastric Adenocarcinoma

    phase 2 small molecule completed

    1 trial

  5. Randomized phase 2 trial of two chemotherapy regimens plus or minus bevacizumab in patients with well differentiated pancreatic neuroendocrine tumors

    The George Institute

    Pancreatic well differentiated neuroendocrine tumors (NET)

    phase 2 other active

    1 trial

  6. Receptor radionuclide therapy with 177Lu-DOTATOC (177Lu- edotreotide or 177Lu-octreotide) in SSTR positive patients: a multicenter, prospective, phase II trial

    Istituto Gentili S.r.l.

    NET, Neuroendocrine Tumor, Other SSTR-positive tumours, NETs retreated with PRRT, Pheochromocytomas and paragangliomas, Bronchopulmonary and other NETs

    phase 2 other active

    1 trial

  7. Recombinant Human Endostatin Injection

    The First People's Hospital of Lianyungang

    Locally Advanced Squamous Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  8. Recombinant anti-PD-1 humanized monoclonal antibody injection

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Sarcoma, Soft Tissue

    phase 2 small molecule active

    1 trial

  9. Recombinant human endostatin

    The First People's Hospital of Lianyungang

    Stage III Non-small-Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  10. Regorafenib

    United Therapeutics Europe Ltd

    Adenocarcinoma of the Gastroesophageal Junction

    phase 2 small molecule terminated

    1 trial

  11. Relacorilant

    CORCEPT THERAPEUTICS INC

    Recurrent Ovarian Cancer

    phase 2 small molecule completed

    1 trial

  12. Relacorilant 150 mg once daily (QD)

    CORCEPT THERAPEUTICS INC

    Ovarian Cancer

    phase 2 small molecule active

    1 trial

  13. Relacorilant 150 mg once daily (QD)

    CORCEPT THERAPEUTICS INC

    Adenocarcinoma

    phase 2 small molecule active

    1 trial

  14. Relacorilant with nab-paclitaxel

    CORCEPT THERAPEUTICS INC

    Solid Tumors

    phase 2 small molecule completed

    1 trial

  15. Relatlimab

    Bristol-Myers Squibb

    Neoplasms by Site

    phase 2 mab completed

    1 trial

  16. Relugolix

    Takeda

    Prostate Cancer

    phase 2 small molecule completed

    1 trial

  17. Repotrectinib (TPX-0005)

    Turn Therapeutics

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  18. Repotrectinib (TPX-0005), Repotrectinib (TPX-0005), Repotrectinib (TPX-0005)

    Turn Therapeutics

    Advanced solid tumors

    phase 2 small molecule active

    1 trial

  19. Retifanlimab (INCMGA00012), HOLOXAN 2000 mg, poudre pour usage parentéral, DOXORUBICINE ACCORD 2 mg/ml, solution pour perfusion

    The George Institute

    Adult patients with treatment-naïve surgically non-metastatic and resectable primary retroperitoneal, limbs and trunk wall undifferentiated pleomorphic sarcomas.

    phase 2 small molecule active

    1 trial

  20. Revlimid 25 mg hard capsules, DexaGalen® 8 mg injekt Injektionslösung, Revlimid 20 mg hard capsules, Pomalidomide Adalvo 3 mg hard capsules, Imnovid 4 mg hard capsules, Imnovid 1 mg hard capsules, Zelvina 5 mg hard capsules, LIBTAYO 350 mg concentrate for solution for infusion., Imnovid 4 mg hard capsules, DIPHENHYDRAMINE , Revlimid 15 mg hard capsules, MONTELUKAST , JAMP Pomalidomide, PARACETAMOL , Revlimid 20 mg hard capsules, Imnovid 3 mg hard capsules, Imnovid 1 mg hard capsules, Revlimid 25 mg hard cap

    Sanofi-aventis Healthcare Pty Ltd

    Cancer

    phase 2 small molecule active

    1 trial

  21. Revlimid 5 mg hard capsules, DEXAMETHASONE, DEXAMETHASONE , DARZALEX 1800 mg solution for injection, BORTEZOMIB , Revlimid 10 mg hard capsules, BORTEZOMIB, DEXAMETHASONE

    Pari Pharma GmbH

    PRIMARY PLASMA CELL LEUKEMIA: A PROSPECTIVE PHASE II STUDY INCORPORATING DARATUMUMAB TO CHEMOTHERAPY AND STEM CELL TRANSPLANTATION

    phase 2 small molecule active

    1 trial

  22. Revumenib

    Syndax Pharmaceuticals

    Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  23. Revumenib

    Syndax Pharmaceuticals

    Leukemia

    phase 2 small molecule active

    1 trial

  24. Revumenib

    Syndax Pharmaceuticals

    Acute Myeloid Leukemia

    phase 2 small molecule active

    2 trials

  25. Revumenib, Revumenib, SNDX-5613, Revumenib, Revumenib, SNDX-5613

    Syndax Pharmaceuticals

    Relapsed or Refractory Acute Leukemias

    phase 2 small molecule active

    1 trial

  26. Rezvilutamide

    Nanjing Zenshine Pharmaceuticals

    Prostate Cancer

    phase 2 small molecule active

    1 trial

  27. Rezvilutamide

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Metastatic Hormone-Sensitive Prostate Cancer

    phase 2 small molecule active

    1 trial

  28. Rilvegostomig, Rilvegostomig

    AstraZeneca AB

    Advanced Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, stage III unresectable Non-small Cell Lung Cancer (Protocol Parts A-B), stage IV Non-small Cell Lung Cancer (Protocol Parts A-E).

    phase 2 small molecule active

    1 trial

  29. Ritonavir

    Abbott Australasia Pty Ltd

    Sarcoma, Kaposi

    phase 2 small molecule completed

    1 trial

  30. Rituximab

    BEONE MEDICINES AUS PTY LTD

    Chronic Lymphocytic Leukemia

    phase 2 mab active

    1 trial

  31. Rituximab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Diffuse Large B Cell Lymphoma

    phase 2 small molecule active

    1 trial

  32. Rituximab Paclitaxel Ruxolitinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Refractory Diffuse Large B-cell Lymphoma

    phase 2 small molecule active

    1 trial

  33. RoActemra 20 mg/mL concentrate for solution for infusion, CD19 4-1 BBL, Gazyvaro 1,000 mg concentrate for solution for infusion., Columvi 10 mg concentrate for solution for infusion

    Hoffmann-La Roche

    Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (r/r B-cell NHL)

    phase 2 small molecule active

    1 trial

  34. RoActemra 20 mg/mL concentrate for solution for infusion, Glofitamab

    Hoffmann-La Roche

    Diffuse Large B-Cell Lymphoma

    phase 2 small molecule active

    1 trial

  35. Roginolisib

    United Therapeutics Europe Ltd

    Leukemia

    phase 2 small molecule active

    1 trial

  36. Romidepsin

    Fondazione Telethon ETS

    Anaplastic Large T-cell Lymphoma ALK negative, Angioimmunoblastic T-cell Lymphoma, Peripheral T-cell lymphoma, NOS

    phase 2 small molecule active

    1 trial

  37. Romidepsin

    Takeda

    Lymphoma, T-Cell, Peripheral

    phase 2 small molecule terminated

    1 trial

  38. Rozlytrek 200 mg hard capsules

    Hoffmann-La Roche

    Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

    phase 2 small molecule active

    1 trial

  39. Rozlytrek, Rozlytrek, Rozlytrek

    Hoffmann-La Roche

    Pediatric Solid tumors and primary central nervous system (CNS) tumors

    phase 2 small molecule active

    1 trial

  40. Rubraca 300 mg film-coated tablets, Rubraca 200 mg film-coated tablets, BEVACIZUMAB, Rubraca 250 mg film-coated tablets, CARBOPLATIN, PACLITAXEL

    Fondazione Telethon ETS

    Advanced (stage III B-C-IV) ovarian, primary peritoneal and Fallopian tube cancer.

    phase 2 small molecule active

    1 trial

  41. Rucaparib

    United Therapeutics Europe Ltd

    Cervical Cancer

    phase 2 small molecule terminated

    1 trial

  42. Rydapt 25 mg soft capsules, Dacogen 50 mg powder for concentrate for solution for infusion., Rydapt 25 mg soft capsules

    Wuhan Createrna Science and Technology Co., Ltd

    Acute myeloid leukemia, Myelodysplastic syndrome

    phase 2 small molecule active

    1 trial

  43. S-1

    United Therapeutics Europe Ltd

    Locally Advanced or Metastatic Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  44. S-1

    United Therapeutics Europe Ltd

    Advanced Non-Small Cell Lung Cancer

    phase 2 small molecule completed

    2 trials

  45. S095018

    Regeneron UK Limited

    Non-small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  46. S095029/Sym025, LIBTAYO 350 mg concentrate for solution for infusion., S095018/Sym023, S095024/Sym024

    The George Institute

    Non-small cell lung cancer (NSCLC): - Locally advanced NSCLC where participants are not candidates for surgical resection and/or definitive chemoradiation, or - Metastatic NSCLC

    phase 2 small molecule active

    1 trial

  47. S095035

    Tango Therapeutics

    MTAP-deleted Solid Tumors

    phase 2 small molecule active

    1 trial

  48. S1

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Metastatic Gastric Adenocarcinoma

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,568 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.